Aligos Therapeutics, Inc.
(NASDAQ : ALGS)

( )
ALGS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.25%162.640.7%$1229.36m
PFEPfizer Inc. 0.99%38.950.9%$1049.85m
MRKMerck & Co., Inc. 0.18%77.610.7%$782.74m
ABBVAbbVie, Inc. 0.76%108.731.9%$744.24m
BMYBristol-Myers Squibb Co. 0.44%65.751.0%$703.61m
LLYEli Lilly & Co. 0.25%189.731.1%$539.14m
AZNAstraZeneca Plc 1.75%51.631.2%$494.28m
GSKGlaxoSmithKline Plc 0.64%37.990.2%$223.56m
NVSNovartis AG 0.40%88.370.2%$162.95m
VTRSViatris, Inc. -1.12%13.250.0%$124.35m
CVACCureVac NV 3.40%113.000.0%$103.24m
RPRXRoyalty Pharma Plc -0.24%41.770.2%$91.76m
RGENRepligen Corp. -0.59%212.046.8%$80.03m
NVONovo Nordisk A/S 0.75%72.710.1%$62.90m
SNYSanofi 1.01%51.820.2%$59.75m

Company Profile

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.